1. Rol de la IO en el Tratamiento del Cáncer Renal: CheckMate 214
Enrique Grande
Head of Medical Oncology
Director of Clinical Research

2. Disclosures Honoraria for ad boards and/or lectures:
Pfizer, BMS, IPSEN, Roche, Eisai, Eusa Pharma, MSD, Sanofi-Genzyme, Adacap, Novartis, Pierre Fabre, Lexicon, Celgene
Research Grants:
Pfizer, Astra Zeneca, MTEM/Threshold, Roche, IPSEN, Lexicon
Leadership roles in medical societies:
ENETS, GETNE and GETHI
Stocks or ownership interest:
None

3. ESMO 2019 Guidelines 1st Line mRCC
Escudier B, et al. Ann Oncol 2019

4. Current European Association of Urology updated Guidelines
Powles T, et al. Eur Urol 2017

5. CheckMate 214: Changing paradigms in mRCC
Motzer RJ, et al. N Engl J Med 2018

6. Curti BD. N Engl J Med 2018

7. Curti BD. N Engl J Med 2018

8. CheckMate 214 Trial Design
Motzer RJ, et al. N Engl J Med 2018

9. CheckMate 214: Baseline characteristics
Motzer RJ, et al. N Engl J Med 2018

10. CheckMate 214: Overall Survival in the ITT (follow up 30m)
Tannir N, et al. ASCO GU 2019

11. CheckMate 214: Overall Survival by IMDC Risk
Tannir N, et al. ASCO GU 2019

12. CheckMate 214: Investigator-Assessed PFS ITT Patients
Tannir N, et al. ASCO GU 2019

13. CheckMate 214: Investigator-Assessed PFS by IMDC risk
Tannir N, et al. ASCO GU 2019

14. CheckMate 214: Time from randomization to subsequent systemic anticancer therapy initiation or death in the ITT population
McDermott DF, et al. ASCO GU 2019

15. CheckMate 214: Time from randomization to subsequent systemic anticancer therapy initiation or death in IMDC favorable risk pts
McDermott DF, et al. ASCO GU 2019

16. Treatment Free Survival health states and endpoints
McDermott DF, et al. ASCO GU 2019

17. Treatment Free Survival in ITT patients who discontinued protocol therapy
McDermott DF, et al. ASCO GU 2019

18. Treatment Free Survival in IMDC favorable-risk patients who discontinued protocol therapy
McDermott DF, et al. ASCO GU 2019

19. TFS in IMDC Intermediate/Poor-Risk Patients Who Discontinued
Protocol Therapy and Had CR/PR or SD
McDermott DF, et al. Oral presentation at the 7th International Kidney Cancer Simposium. Miami 2018

20. CheckMate 214: Investigator-Assessed Response by RECIST v1.1
Tannir N, et al. ASCO GU 2019

21. CheckMate 214: Objective response rate by Age
Motzer RJ, et al. N Engl J Med 2018

22. CheckMate 214: Duration of Response
Rini BI, et al. Presented at the 17th International Kidney Cancer Symposium; November 2–3, 2018; Miami, FL, USA

23. CheckMate 214: Overall Survival
Rini BI, et al. Presented at the 17th International Kidney Cancer Symposium; November 2–3, 2018; Miami, FL, USA

24. CheckMate 214 Trial: Treatment-related AEs ITT
Motzer RJ, et al. N Engl J Med 2018

25. CheckMate 214 Trial: Time to onset of any-grade treatment-related select AEs in the NIVO+IPI arm
Tannir N, et al. Presented at the 13th European International Kidney Cancer Symposium; April 27–28, 2018; Prague, Czech Republic

26. Treatment-Related AEs Over Time by Most
Common System Organ Class (All Treated Patients)
Tannir N, et al. ASCO GU 2019

27. Treatment-related Aes leading to discontinuation within 100 days of last dose in the NIVO+IPI arm
Tannir N, et al. ASCO GU 2019

28. Total NIVO doses received in pts who discontinued due to treatment-related AEs in the NIVO+IPI arm
Tannir N, et al. ASCO GU 2019

29. Best Overall Response per Investigator by AEs
Tannir N, et al. ASCO GU 2019

30. Overall Survival by treatment-related AEs discontinuation
Tannir N, et al. ASCO GU 2019

31. Cella D, et al. Lancet Oncol 2019

32. CheckMate 214: Patient-reported Outcomes (FKSI-19)
Cella D, et al. Lancet Oncol 2019

33. CheckMate 214: Cost-effectiveness Analysis
Wam XM, et al. JAMA Oncol 2019

34.
@drenriquegrande